VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
Follow VTGN
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
45.40 | 80.48 | 119.17 | 16.64 | 68.14 | 103.11 | 1.36 | 13.10 | 10.38 | 2.92 |
Receivables |
— | — | — | — | — | — | — | 0.30 | — | — |
Total current assets |
46.94 | 82.08 | 120.67 | 17.51 | 71.00 | 104.12 | 1.58 | 13.63 | 11.02 | 3.38 |
Property, Plant, Equpment (Net) |
0.43 | 0.48 | 0.44 | 0.51 | 0.41 | 0.37 | 0.21 | 0.31 | 0.21 | 0.29 |
Long-term assets (Other) |
0.39 | 0.45 | 0.73 | 0.10 | 0.10 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
Total non-current assets |
1.62 | 2.27 | 2.98 | 3.58 | 3.65 | 4.16 | 4.19 | 0.38 | 0.26 | 0.33 |
Total Assets |
48.56 | 84.34 | 123.65 | 21.09 | 74.64 | 108.28 | 5.77 | 14.01 | 11.28 | 3.71 |
Notes Payable |
0.10 | — | — | 0.11 | — | — | 0.06 | 0.06 | 0.05 | 0.05 |
Accounts Payable |
1.54 | 0.65 | 1.55 | 2.47 | 2.76 | 0.84 | 1.84 | 1.06 | 1.20 | 0.87 |
Accrued Expenses |
8.76 | 8.81 | 2.24 | 0.80 | 1.33 | 1.56 | 0.56 | 1.69 | 0.21 | 0.44 |
Current Part of Capital Lease |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Current Revenue (Deferred) |
1.71 | 2.59 | 0.79 | 0.71 | 1.24 | 1.42 | — | — | — | — |
Total current liabilities |
12.80 | 12.61 | 5.12 | 4.57 | 5.77 | 4.19 | 2.77 | 2.80 | 1.46 | 1.37 |
Long Term Debt (Total) |
— | — | — | — | — | — | 0.00 | 0.01 | 0.01 | 0.01 |
Non-current Revenue (Deferred) |
— | 0.39 | 2.67 | 2.32 | 1.56 | 2.49 | — | 0.38 | 0.29 | 0.14 |
Non-current Liabilities (Other) |
— | — | — | — | — | 6.27 | 5.01 | 3.75 | 2.61 | 1.58 |
Total non-current liabilities |
0.25 | 1.34 | 4.24 | 4.44 | 4.16 | 12.11 | 8.73 | 4.14 | 2.90 | 1.73 |
Total liabilities |
13.04 | 13.95 | 9.37 | 9.01 | 9.93 | 16.30 | 11.50 | 6.94 | 4.36 | 3.10 |
Additional Paid In Capital |
516.77 | 481.96 | 474.44 | 342.89 | 336.28 | 315.60 | 200.09 | 192.13 | 167.40 | 146.57 |
Preferred Stock (Total) |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Common Stock (Net) |
0.04 | 0.03 | 0.03 | 0.01 | 0.01 | 0.18 | 0.05 | 0.04 | 0.02 | 0.01 |
Retained Earnings |
(477.32) | (407.63) | (356.21) | (326.85) | (267.60) | (219.84) | (201.91) | (181.13) | (156.54) | (142.00) |
Treasury Stock |
3.97 | 3.97 | 3.97 | 3.97 | 3.97 | 3.97 | 3.97 | 3.97 | 3.97 | 3.97 |
Common Equity (Total) |
35.52 | 70.39 | 114.29 | 12.08 | 64.72 | 91.97 | (5.73) | 7.07 | 6.91 | 0.61 |
Shareholders Equity (Total) |
35.52 | 70.39 | 114.29 | 12.08 | 64.72 | 91.98 | (5.73) | 7.08 | 6.92 | 0.62 |
Shareholders Equity and Liabilities (Total) |
48.56 | 84.34 | 123.65 | 21.09 | 74.64 | 108.28 | 5.77 | 14.01 | 11.28 | 3.71 |
Shares (Common) |
39.62 | 29.00 | 27.03 | 7.32 | 6.89 | 6.01 | 1.64 | 1.42 | 0.76 | 0.30 |
Shares (Preferred) |
— | — | — | — | — | 0.14 | 0.13 | 0.13 | 0.12 | 0.13 |
Shareholders Equity (Tangible) |
35.52 | 70.39 | 114.29 | 12.08 | 64.72 | 91.98 | (5.73) | 7.08 | 6.92 | 0.62 |
Net Debt |
(45.40) | (80.48) | (119.17) | (16.64) | (68.14) | (103.11) | (1.35) | (13.09) | (10.37) | (2.91) |
Total Debt |
— | — | — | 0.60 | 3.04 | 3.72 | 0.00 | 0.01 | 0.01 | 0.01 |